We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Heart Attack Test Delivers Results in One Hour

By LabMedica International staff writers
Posted on 27 Aug 2012
Print article
A more sensitive blood test for heart attack may cut the diagnosis time to one hour, removing the need for prolonged monitoring of patients who present to the Emergency Department (ED).

The test, which screens more sensitively for changes in a standard biochemical marker for myocardial infarction or heart attack, may help move patients more quickly through the ED, thus reducing congestion and saving time and money.

Scientists at the University Hospital Basel (Switzerland) recruited 872 patients who presented to the ED with acute chest pain in a multicenter study. The cornerstone for diagnosing acute myocardial infarction (AMI) relies on clinical assessment, electrocardiography and measurement of a biochemical marker called cardiac troponin (or cTn). Without a rapid test for the marker, it can take three hours or more to check for increases in levels.

Blood samples for the determination of high-sensitivity cardiac troponin (hs-cTnT) were collected in serum tubes at presentation to the ED and additional samples were collected hourly thereafter. The samples were assayed in a blinded fashion using the Elecsys 2010 analyzer (Roche Diagnostics; Basel Switzerland). The team developed an algorithm for half of the patients and validated it in the remaining half. The algorithm used baseline hs-cTnT and absolute changes in levels of the biochemical marker within the first hour.

The final diagnosis of AMI was made in 147 (17%) of the patients. When they validated the test in the second group of patients, within one hour it classed 60% (259 patients) of them as rule-out, 17% (76) as rule-in, and 23% (101) as being in the observational zone. They found the cumulative 30-day survival was nearly 100%, 98.6% and 95.3% for patients classed as rule-out, observational zone, and rule-in respectively.

Tobias Reichlin, MD, the lead author of the study said, "Using a simple algorithm incorporating hs-cTnT baseline values and absolute changes within the first hour allowed a safe rule-out as well as an accurate rule-in of AMI within one hour in 77% of unselected patients with acute chest pain. This novel strategy may obviate the need for prolonged monitoring and serial blood sampling in three of four patients." The study was published on August 13, 2012, in the journal Archives of Internal Medicine.

Related Links:

University Hospital Basel
Roche Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: The test monitors blood levels of DNA fragments released by dying tumor cells (Photo courtesy of 123RF)

Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer

Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.